Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R, Gibiansky L, Lu T, Flowers CR, Sehn LH, Liu Q, Agarwal P, Liao MZ, Dere R, Lee C, Man G, Hirata J, Li C, Miles D. Deng R, et al. Among authors: flowers cr. CPT Pharmacometrics Syst Pharmacol. 2024 Apr 15. doi: 10.1002/psp4.13141. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38622879 Free article.
Defining Primary Refractory Large B-cell Lymphoma.
Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks TW, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. Bock AM, et al. Among authors: flowers cr. Blood Adv. 2024 Apr 26:bloodadvances.2024012760. doi: 10.1182/bloodadvances.2024012760. Online ahead of print. Blood Adv. 2024. PMID: 38669353
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Marin D, et al. Among authors: flowers cr. Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18. Nat Med. 2024. PMID: 38238616 Free PMC article. Clinical Trial.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. Cerhan JR, et al. Among authors: flowers cr. Am J Hematol. 2024 Mar;99(3):408-421. doi: 10.1002/ajh.27202. Epub 2024 Jan 13. Am J Hematol. 2024. PMID: 38217361
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SM, Stephens DM, Bachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzmán A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, Bi C; North American Mantle Cell Lymphoma Consortium. Vose JM, et al. Among authors: flowers cr. J Hematol Oncol. 2023 Dec 16;16(1):122. doi: 10.1186/s13045-023-01520-7. J Hematol Oncol. 2023. PMID: 38104096 Free PMC article.
398 results